Released Mar 25, 2024, after the close
10-K filed Mar 25, 2024, 85 days after period end · 0000950170-24-035949
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$113.72M$113.72M derived+1,217.4% vs Q4 2022+572.0% vs Q3 2023
Net Income$31.07M$31.07M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$43,152,000N/M
Operating Cash Flowderived$14,072,000N/M
Margins · derived
Operating margin37.9%+608.2 pt vs Q4 2022
Net margin27.3%+428.1 pt vs Q4 2022
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $113.72M | $8.63M | $10.65M | $8.28M |
| Net Income | $31.07M | -$34.59M | -$38.13M | -$59.54M |
| EPS Diluted | — | — | — | -$1.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR